Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Letrozole - Novartis

Drug Profile

Letrozole - Novartis

Alternative Names: CGP 20267; CGS 20267; Femara

Latest Information Update: 08 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Eli Lilly and Company; Gynecologic Oncology Group; International Breast Cancer Study Group; M. D. Anderson Cancer Center; National Cancer Institute (USA); Novartis; Roche; University of Colorado at Denver
  • Class Antineoplastics; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer
  • Discontinued Delayed puberty; Endometriosis; Female infertility

Most Recent Events

  • 31 May 2019 Interim efficacy and adverse events data from the phase-IIIb CompLEEment-1 trial in Breast cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 25 Feb 2019 Novartis Pharmaceuticals initiates a phase II RIGHT Choice trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Malaysia and Taiwan (PO) (NCT03839823)
  • 24 Dec 2018 Phase-II clinical trials in Endometrial cancer (Second-line therapy or greater, Recurrent, Combination therapy) in USA (PO) (NCT03675893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top